糖基因 ST8SIA4在人慢性粒细胞白血病多药耐药中的作用研究

目的：通过研究糖基因 ST8SIA4在人慢性粒细胞白血病（CML ）细胞株 KCL22及其耐阿霉素（ADR）细胞株KCL22／ADR 、CML 患者外周血单个核细胞（PBMC）中表达的差异，明确糖基因 ST8SIA4与人 CML 多药耐药的相关性。方法采用 RT-PCR 和 Western Blot 检测糖基因 ST8SIA4在人 CML 及其耐药细胞株、CML 及 CML 耐药患者 PBMC 中的表达；特异性下调糖基因 ST8SIA4，检测干扰前、后 CML 细胞在体外对化疗药物的敏感性。结果糖基因 ST8SIA4在人 CML 及其耐药细胞株、CML 患者 PBMC 中表达水平比较差异有统计学意义（P＜0．05）；特异性下调 ST8SIA4的表达，增加了 KCL22／ADR 细胞体内、体外的药敏性（P＜0．05）。结论人 CML 细胞株及 CML 患者 PBMC 中糖基因 ST8SIA4的表达差异有统计学意义，这些特征性改变与 CML 多药耐药具有相关性。

The correlation study of the glycogene ST8SIA4 in the multidrug resistance of human chronic myeloid leukemia

Objective To investigate the differential expression of ST8SIA4 in the both chronic myeloid leukemia(CML) cell lines KCL22 and adriamycin resistant cell lines KCL22/ADR ,peripheral blood mononuclear cells (PBMC) of CML patients ,to clar-ify the correlation of ST8SIA4 and multidrug resistance of CML .Methods Using real-time PCR and Western blot for quantification of ST8SIA4 ,we compared the differential expression of ST8SIA4 in CML cell lines and PBMC of CML patients .The differentially expressed ST8SIA4 gene was silenced ,and the chemosensitivity to anti-tumor drugs was analyzed in vitro .Results ST8SIA4 was differentially expressed in CML cell lines and PBMC of CML patients(P< 0 .05) .The altered level of ST8SIA4 was increased drug-resistant phenotype of KCL22/ADR cells both in vitro and in vivo(P< 0 .05) .Conclusion The expression of ST8SIA4 was different in CML cell lines and PBMC of CML patients ,these characteristic alterations were associated with multidrug resistance in CML .